American Association of Oral and Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis of the Jaws
Top Cited Papers
- 1 March 2007
- journal article
- Published by Elsevier BV in Journal of Oral and Maxillofacial Surgery
- Vol. 65 (3), 369-376
- https://doi.org/10.1016/j.joms.2006.11.003
Abstract
Bisphosphonate-related osteonecrosis of the jaw (BRONJ) adversely affects the quality of life and produces significant morbidity in afflicted patients. Oral and maxillofacial surgeons have been respon- sible for counseling, managing, and treating a ma- jority of these patients. The strategies set forth in this position paper were developed by a Task Force appointed by the American Association of Oral and Maxillofacial Surgeons (AAOMS). The Task Force was composed of clinicians with extensive experi- ence in caring for these patients, clinical epidemi- ologists, and basic science researchers offering a broad range of experience and background. The strategies are based on an analysis of the existing literature and the clinical observations of the expert Task Force members. AAOMS considers it vitally important that this information be disseminated to other dental and medical specialties. It is under- stood that the strategies and treatment algorithms outlined in this article are starting points based on our current understanding of BRONJ. As the knowl- edge base and experience in addressing BRONJ evolves, future modifications and refinements of the current strategies will necessarily be required.Keywords
This publication has 35 references indexed in Scilit:
- Long‐term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumorsCancer, 2004
- Long-Term Efficacy of Zoledronic Acid for the Prevention of Skeletal Complications in Patients With Metastatic Hormone-Refractory Prostate CancerJNCI Journal of the National Cancer Institute, 2004
- American Society of Clinical Oncology 2003 Update on the Role of Bisphosphonates and Bone Health Issues in Women With Breast CancerJournal of Clinical Oncology, 2003
- A Randomized, Placebo-Controlled Trial of Zoledronic Acid in Patients With Hormone-Refractory Metastatic Prostate CarcinomaJNCI Journal of the National Cancer Institute, 2002
- Zoledronic Acid Is Superior to Pamidronate in the Treatment of Hypercalcemia of Malignancy: A Pooled Analysis of Two Randomized, Controlled Clinical TrialsJournal of Clinical Oncology, 2001
- Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group.Journal of Clinical Oncology, 1998
- Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.Journal of Clinical Oncology, 1998
- Efficacy of Pamidronate in Reducing Skeletal Complications in Patients with Breast Cancer and Lytic Bone MetastasesNew England Journal of Medicine, 1996
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: Comparison of 30-, 60-, and 90-mg dosagesAmerican Journal Of Medicine, 1993